stock faces challenges amid pipeline progress By Investing.com
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is navigating a critical phase in its development as a biopharmaceutical company focused on oncology and inflammatory diseases. The company’s proprietary PREDATOR platform forms the backbone of its drug development efforts, with several candidates in various stages of clinical trials. As of January 14, 2025, Werewolf’s stock trades at $1.38, near its 52-week low of $1.31 and significantly below its high of $8.19. With a market capitalization of approximately $60.2 million, the stock has declined over 73% in the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value estimates.
Pipeline Progress and Clinical Trials
Werewolf’s lead…
